Welcome to our dedicated page for MESOBLAST SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESOBLAST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESOBLAST's regulatory disclosures and financial reporting.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026. The company reports that on January 9, 2026 it filed a news release announcement with the Australian Securities Exchange, which is included with this submission as Exhibit 99.1 and incorporated by reference. This filing mainly serves to make that Australian disclosure available to U.S. investors.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information also lodged on the Australian Securities Exchange.
On January 6, 2026, the company filed in Australia a new issue announcement and notification of cessation of securities (Appendix 3H) and a new issue announcement and change of director’s interest notice (Appendix 3Y). These ASX documents are attached to the Form 6-K as Exhibits 99.1 and 99.2 and are incorporated by reference.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026. The company reports that on January 2, 2026, it filed a news release announcement with the Australian Securities Exchange, which is attached to this report as Exhibit 99.1 and incorporated by reference.
The filing is signed on behalf of Mesoblast by Company Secretary Paul Hughes and primarily serves to make the same press release available to U.S. investors through the SEC system.
Mesoblast Limited has filed a Form F-3 to register up to 5,000,000 ordinary shares, represented by 500,000 American Depositary Shares (ADSs), for resale by existing shareholders. These shares are issuable upon exercise of warrants granted in a December 2025 private placement. The ADSs trade on Nasdaq under “MESO” and each ADS equals 10 ordinary shares.
The selling shareholders, including Dr. Gregory George and Dr. William Gueck, will receive all proceeds from any ADS resales, while Mesoblast will only receive US$16.25 per ADS when warrants are exercised. The warrants cover up to 5,000,000 ordinary shares, have a four‑year term, and 3,000,000 of them become exercisable only if Mesoblast elects to issue up to US$50 million of subordinated unsecured convertible notes under related subscription agreements. Ordinary shares outstanding after the offering would be 1,290,802,187.
Mesoblast Limited submitted a foreign issuer report to the U.S. SEC for December 2025. The company notes that on December 23, 2025 it lodged with the Australian Securities Exchange a new issue announcement and a change of director’s interest notice (Appendix 3Y), which is attached as an exhibit to this report and incorporated by reference. The filing is administrative in nature and centers on disclosure of director shareholding changes and related new issue details rather than operating or financial results.
Mesoblast Limited submitted a foreign issuer report describing an action first disclosed on the Australian Securities Exchange. On December 17, 2025, the company lodged an Appendix 3G with the ASX, which relates to a new issue announcement and the issue, conversion or payment up of unquoted equity securities. This Appendix 3G document is attached to the report as an exhibit and is incorporated by reference for further details.